Provided by Tiger Fintech (Singapore) Pte. Ltd.

Intellia Therapeutics

7.92
+0.68509.47%
Volume:4.48M
Turnover:35.68M
Market Cap:819.34M
PE:-1.51
High:8.33
Open:7.36
Low:7.15
Close:7.23
Loading ...

Intellia Therapeutics Shares Rise After Upgrade From Wolfe Research

MT Newswires Live
·
1 hour ago

Intellia Therapeutics upgraded at Wolfe on sentiment, valuation

TIPRANKS
·
Yesterday

Wolfe Research Upgrades Intellia Therapeutics to Outperform From Peer Perform, Price Target is $21

MT Newswires Live
·
Yesterday

Intellia Therapeutics upgraded to Outperform from Peer Perform at Wolfe Research

TIPRANKS
·
Yesterday

NTLA Lawsuit Alert! Class Action Lawsuit Against Intellia Therapeutics Inc.

TIPRANKS
·
14 Apr

Intellia Therapeutics, Inc. (NTLA): Among Stocks Under $10 that Will Triple

Insider Monkey
·
09 Apr

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
04 Apr

Intellia Therapeutics announces first patient dosed in MAGNITUDE-2 trial

TIPRANKS
·
03 Apr

BRIEF-Intellia Therapeutics Announces First Patient Dosed In The Magnitude-2 Phase 3 Study Of Nexiguran Ziclumeran (Nex-Z), Treatment For Transthyretin (Attr) Amyloidosis With Polyneuropathy

Reuters
·
03 Apr

Intellia Therapeutics Inc: Plans to Submit a Biologics Licensing Application for Attrv-Pn by 2028

THOMSON REUTERS
·
03 Apr

Intellia Therapeutics Announces First Patient Dosed in the Magnitude-2 Phase 3 Study of Nexiguran Ziclumeran (Nex-Z), a One-Time Gene Editing-Based Treatment for Transthyretin (Attr) Amyloidosis With Polyneuropathy

THOMSON REUTERS
·
03 Apr

Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy

GlobeNewswire
·
03 Apr

RBC Cuts Price Target on Intellia Therapeutics to $32 From $37, Keeps Outperform, Speculative Risk

MT Newswires Live
·
03 Apr

Is Intellia Therapeutics, Inc. (NTLA) the Best Gene-Editing Stock to Buy?

Insider Monkey
·
02 Apr

Biotech stocks slide as Marks resignation seen being negative for sector

TipRanks
·
01 Apr

Intellia Focuses on Pipeline Development Amid Stiff Competition

Zacks
·
31 Mar

Promising Genomics & Synthetic Biology Stocks to Consider in 2025

Zacks
·
28 Mar

Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Wave Life Sciences (WVE)

TIPRANKS
·
26 Mar

Intellia Therapeutics' Gene-Editing Drug Gets FDA Designation

MT Newswires Live
·
26 Mar

BRIEF-Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z)

Reuters
·
26 Mar